Citations

Showing 10 of 108104 citations.

Pulmonary Function Assessment Post-Left Ventricular Assist Device Implantation
Sajgalik, Pavol , Kim, Chul‐Ho , Stulak, John M., Kushwaha, Sudhir S. , Maltais, Simon, Joyce, David L. , Joyce, Lyle D., Johnson, Bruce D. , Schirger, John A.

Mayo Clinic

ESC Heart Failure | October 12, 2018 | Volume: 6 | Issue: 1 | Pages: 53-61

10.1002/ehf2.12348 | PMID 30311748 Get It

Abstract Aim The lungs—and particularly the alveolar-capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and diffusing capacity of the lung for carbon monoxide (DLCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9) years; male sex, n = 33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237 days post-LVAD implantation, we observed significant DLCO decrease (−23%) since pre-implantation (P < 0.001). ΔDLCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: ΔDLCO to ΔPCWP (r = 0.50, P < 0.01) and ΔDLCO to ΔRAP (r = 0.39, P < 0.05). We observed other reductions in FEV1, FVC, and FEV1/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV1 changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV1/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that ΔDLCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28–0.98); P = 0.03]. Conclusions Pulmonary function did not improve after LVAD implantation. The degree of DLCO deterioration is related to haemodynamic status post-LVAD implantation. The ΔDLCO within 6 months post-operative was associated with survival.
Left Ventricular Assist Devices: How Do We Define Success?
Anwer, Lucman A. , Poddi, Salvatore , Tchantchaleishvili, Vakhtang , Daly, Richard C. , Toeg, Hadi , Strand, Jacob J. , Stulak, John M., Maltais, Simon, Tchantchaleishvili, Vakhtang

Mayo Clinic

ASAIO Journal | October 12, 2018 | Volume: 65 | Issue: 5 | Pages: 430-435

10.1097/mat.0000000000000894 | PMID 30312213 Get It

Despite the growing acceptance of left ventricular assist device (LVAD) therapy to improve survival and quality of life in heart failure (HF) patients, uncertainties persist regarding the definition of a successful implant. We sought to define an innovative approach to assess success and subsequently compare preoperative variables affecting outcomes. From January 2007 to 2015, 278 patients underwent LVAD implantation. Median age at implant was 62 years and 81% patients were males. Indication for support was bridge-to-transplantation in 36% patients and the etiology of HF was ischemic in 49% patients. Based on clinically relevant and accepted standards, we defined successful LVAD implant as someone who was alive or transplanted at 2 years, had two or less readmissions in the first year, had no major adverse events in the first year, and had a New York Heart Association class of ≤ II at 6 months. Follow-up was obtained for a median of 1.7 years for a total of 605 patient-years-of-support. Based on our criteria, 81/278 (29%) patients were defined as having a successful implant. Univariate predictors of LVAD failure included destination therapy indication (hazard ratio [HR] = 2.11 [1.24, 3.58]), ischemic cardiomyopathy (HR = 1.73 [1.02, 2.94]), and a higher left ventricular ejection fraction (HR = 1.54 [1.07, 2.22]). After multivariable analysis, only destination therapy indication (HR = 2.2 [1.28, 3.78]) was found to be independently predictive of success failure. Despite an overall trend toward improved outcomes on device therapy, our criteria classified only one-third of patients as successful. Continued improvements in adverse event profiles, appropriate patient selection, and optimal time of implantation, together hold the key to improve outcomes after LVAD therapy.
Porphyria Attack Manifesting as Delayed Emergence and Precipitated by Prolonged Cardiopulmonary Bypass: A Case Report of 2 Novel Observations
Cai, Yi , Ratzlaff, Robert A. , Ratzlaff, Robert, Renew, J. Ross

Mayo Clinic

A&A Practice | October 12, 2018 | Volume: 12 | Issue: 8 | Pages: 288-291

10.1213/xaa.0000000000000912 | PMID 30312175 Get It

Acute porphyria is a group of rare disorders in the biosynthesis pathway of heme that can result in severe neurovisceral attacks leading to morbidity and mortality. Perioperative complications have been largely prevented due to avoidance of precipitants and early treatment of symptoms. However, these measures may not always be successful, because not all physiological stressors can be evaded. This case illustrates a porphyria attack precipitated by prolonged cardiopulmonary bypass that manifested as postoperative delayed emergence, failure to wean from mechanical ventilation, autonomic insufficiency requiring significant vasoactive agents, and, ultimately, failure to thrive. The patient passed after withdrawal of care.
Novel Single-Needle Approach for Retrocrural Celiac Plexus Blockade Using Fluoroscopic Guidance: A Case Report
Trousdale, Eleanor R. , Lamer, Tim J. , Warner, Nafisseh S.

Mayo Clinic

A&A Practice | October 12, 2018 | Volume: 12 | Issue: 8 | Pages: 281-284

10.1213/xaa.0000000000000910 | PMID 30312174 Get It

Celiac plexus neurolysis has been shown to be an effective analgesic option for patients with visceral pain related to intraabdominal malignancies. In the setting of significant tumor burden, the celiac plexus may be inaccessible, limiting the efficacy of the transcrural approach. This case report describes a novel single-needle approach to retrocrural celiac plexus blockade, allowing for rapid blockade with a needle trajectory contralateral to the aorta in a 73-year-old woman with altered anatomy secondary to advanced metastatic colorectal cancer.
Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
Chu, Yaya, Shah, Tishi, Yin, Changhong , Barth, Matthew J. , Miles, Rodney R., Ayello, Janet, Morris, Erin , Harrison, Lauren , Ven, Carmella van de , Galardy, Paul J. , Goldman, Stanton, Lim, Megan S. , Hermiston, Michelle L. , McAllister‐Lucas, Linda M. , Giulino‐Roth, Lisa , Perkins, Sherrie L., Cairo, Mitchell S. , Galardy, Paul J , Lee, Sanghoon , Lim, Megan S

Mayo Clinic

OncoImmunology | October 11, 2018 | Volume: 8 | Issue: 1 | Pages: No page available

10.1080/2162402x.2018.1512455 | PMID 30546948 Get It

Loss of RNF40 Decreases NF-κB Activity in Colorectal Cancer Cells and Reduces Colitis Burden in Mice
Chua, Robert Lorenz , Qui, Martin , Saul, Dominik , Mehlich, Dawid , Schildhaus, Hans‐Ulrich , Faubion, William A. , Johnsen, Steven A. , Johnsen, Steven A , Kosinsky, Robyn Laura , Ströbel, Philipp , Wegwitz, Florian , Saul, Dominik

Mayo Clinic

Journal of Crohn's and Colitis | October 11, 2018 | Volume: 13 | Issue: 3 | Pages: 362-373

10.1093/ecco-jcc/jjy165 | PMID 30321325 Get It

AbstractBackground and AimsInflammatory bowel diseases are linked to an increased risk of developing colorectal cancer [CRC]. Previous studies suggested that the H2B ubiquitin ligase RING finger protein-20 [RNF20] inhibited inflammatory signaling mediated by the nuclear factor kappa-light-chain-enhancer of activated B cells [NF-κB]. However, the role of RNF40, the obligate heterodimeric partner of RNF20, in the context of inflammation and CRC has not been addressed. Here, we examined the effect of RNF40 loss on CRC cells in vitro and on inflammation and inflammatory signaling in vitro and in vivo.MethodsWe evaluated H2Bub1 levels in human and murine colorectal tumors by immunohistochemistry. Moreover, we correlated H2Bub1 and RNF40 levels in vivo and assessed the consequences of RNF40 depletion on cellular phenotype and gene expression in CRC cells in vitro. Finally, we examined the effect of a colon-specific loss of Rnf40 in a murine model of colitis, and assessed both local and systemic inflammation-associated consequences.ResultsIn vitro studies revealed that the tumorigenic phenotype of CRC cells decreased after RNF40 depletion and displayed gene expression changes related to chromosome segregation and DNA replication, as well as decreased induction of several NF-κB-associated cytokines. This effect was associated with decreased nuclear localization of NF-κB following tumor necrosis factor alpha treatment. Consistently, the colon-specific loss of Rnf40 exerted a protective local, as well as systemic, effect following acute colitis.ConclusionsOur findings suggest that RNF40 plays a central role in the maintenance of tumorigenic features and inflammatory signaling by promoting nuclear NF-κB activity.
Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Met
Espinel‐Ingroff, Ana , Turnidge, John , Alastruey‐Izquierdo, Ana , Castro, C. , Chen, Yee‐Chun , Chen, Yan , Chryssanthou, Erja , Dannaoui, Éric , García‐Effrón, Guillermo , Govender, Nelesh P. , Guinea, Jesús , Kidd, Sarah , Lass‐Flörl, Cornelia , Linares-Sicilia, María José, López-Soria, Leire , Magobo, Rindidzani E. , Peláez, Teresa, Quindós, Guillermo , Rodriguez-Iglesia, M. A., Ruiz, Maite, Sánchez, F , Sanguinetti, Maurizio , Shields, Ryan K. , Szweda, Piotr , Wengenack, Nancy L. , Bramati, Simone, Cavanna, C. , DeLuca, C., Grancini, Anna, Negri, C. E., Passera, Marco, Pemán, Javier , Prigitano, Anna , Sala, E., Tejada, M., Alastruey-Izquierdo, A , Dannaoui, E , Govender, N P , Guinea, J , Quindós, G , Sánchez-Reus, F , Sanguinetti, M , Szweda, P , Tortorano, A , Peman, J , Kidd, Sarah E , Botterel, Françoise , Cantón, Rafael , González, Gloria María , Lackner, Michaela , Pipaón, Maite Ruíz-Pérez de , Gelmi, Maria Luisa , Lombardi, Giuseppe , Meletiadis, Joseph

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 11, 2018 | Volume: 63 | Issue: 1 | Pages: No page available

10.1128/aac.01651-18 | PMID 30323038 Get It

Although the Sensititre Yeast-One (SYO) and Etest methods are widely utilized, interpretive criteria are not available for triazole susceptibility testing of Candida or Aspergillus species. We collected fluconazole, itraconazole, posaconazole, and voriconazole SYO and Etest MICs from 39 laboratories representing all continents for (method/agent-dependent) 11,171 Candida albicans , 215 C. dubliniensis , 4,418 C. glabrata species complex, 157 C. guilliermondii ( Meyerozyma guilliermondii ), 676 C. krusei ( Pichia kudriavzevii ), 298 C. lusitaniae ( Clavispora lusitaniae ), 911 C. parapsilosis sensu stricto , 3,691 C. parapsilosis species complex, 36 C. metapsilosis , 110 C. orthopsilosis , 1,854 C. tropicalis , 244 Saccharomyces cerevisiae , 1,409 Aspergillus fumigatus , 389 A. flavus , 130 A. nidulans , 233 A. niger , and 302 A. terreus complex isolates.
Pathology‐on‐a‐Chip: Mimicking Human Pathophysiology in Organ‐on‐Chip Devices (Adv. Biosys. 10/2018)
Al‐kharboosh, Rawan , Quiñones‐Hinojosa, Alfredo , Yeşil-Çeliktaş, Özlem , Hassan, Shabir , Miri, Amir K. , Maharjan, Sushila , Zhang, Yu Shrike

Mayo Clinic

Advanced Biosystems | October 11, 2018 | Volume: 2 | Issue: 10 | Pages: No page available

10.1002/adbi.201870092 Get It